Opus Genetics

Opus Genetics develops gene therapies for the treatment of inherited retinal diseases (IRDs). The company's lead asset, OPGx-LCA5, has shown promising safety and visual improvement in early-stage trials. Opus Genetics was initially a spinout of the RD Fund, the venture arm of the Foundation Fighting Blindness.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount:

Date: 25-Oct-2024

Investors: RD Fund

Markets: Biotechnology, Gene Therapy, Ophthalmic, Health Care, Health Diagnostics, Wellness

HQ: Raleigh, North Carolina, United States

Founded: 2021

Website: https://www.opusgtx.com/

LinkedIn: https://www.linkedin.com/company/opus-genetics

Twitter: https://twitter.com/opusgenetics?lang=en

Instagram: